RPCEC00000391尚未招募1 期
Phase I / II, open-label, adaptive study to evaluate the safety, reactogenicity and immunogenicity of the prophylactic vaccine candidate FINLAY-FR-1A against SARS-CoV-2, in convalescent of COVID-19 in pediatric age (COVID-19) - SOBERANA PLUS PEDIATRIA
Finlay Vaccine Institute (IFV)0 个研究点目标入组 520 人开始时间: 2021年9月28日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 520
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- N/a: Single Arm Study. Masking: Open. Control Group: Uncontrolled. Assignment: Single Group. Purpose: Prevention
入排标准
- 年龄范围
- 2 years 至 18 years（—）
- 性别
- All
入选标准
- •1. Subjects aged between 2 and 18 years.
- •2. Voluntariness expressed through informed consent to participate in the study:
- •- Subjects aged 2-11 years: Informed consent of parents or legal guardians.
- •- Subjects aged 12-18 years: Informed Consent of the parents or legal guardians and Informed Assent of the adolescent.
- •3. Weight-height nutritional assessment between the 10th and 90th percentile (for subjects between 2 and 9 years of age) or the BMI between the 10th and 90th percentile for subjects between 10 and 18 years of age), according to the cut-off points for the Cuban pediatric population.
- •4. General, regional and apparatus physical examination without alterations.
- •5. Laboratory results within or outside the range of reference values ??but not clinically significant (For the subjects to be included in phase I).
- •6. Women of childbearing potential use safe contraceptive methods during the study.
排除标准
- •1. Subjects with a history of COVID-19 who meet any of the following criteria:
- •a) Current history of infection or have received a medical discharge for SARS-CoV 2 in the two months prior to recruitment.
- •b) History of critical clinical picture due to COVID-19, according to your medical history or obtained during the medical interview.
- •2. Subject with a history of having received any dose of vaccine candidates or vaccines against SARS - CoV - 2.
- •3. Subjects with acute febrile or infectious disease in the 7 days prior to the administration of the vaccine or at the time of its application.
- •4. Subjects with antimicrobial treatment or sustained treatment with NSAIDs in the 7 days prior to the administration of the vaccine.
- •5. Subjects with chronic non-communicable diseases NOT controlled, according to clinical or laboratory criteria (bronchial asthma, chronic obstructive pulmonary disease, ischemic heart disease, arterial hypertension, diabetes mellitus, thyroid, neurological, hemolymphopoietic system diseases, liver failure, kidney failure , psychiatric illness at a psychotic level, among others).
- •6. Subjects with congenital or acquired immune system disease.
- •7. Subjects with a history of neoplastic disease.
- •8. Subjects with a history of substance abuse in the past 30 days or substance addictive illness, except smoking.
- •9. Subjects with diminished mental faculties.
- •10. Subjects with a history of severe allergic disease (anaphylactic shock, angioneurotic edema, glottis edema, severe urticaria).
- •11. Participation in another clinical trial of preventive or therapeutic intervention in the last 3 months.
- •12. Application of another vaccine in the last 30 days.
- •13. Treatment with immunomodulators in the last 30 days, eg; steroids (except for the occasional use of topical or inhaled steroids), cytostatics, interferon, immunoferon, transfer factor, monoclonal antibodies, biomodulin T, any ganmaglobulin, levamisole, heberferon, thymosin) or those who, due to their underlying disease, require treatment immunomodulator, which may coincide during the development of the study.
- •14. History of having received a blood transfusion or blood products in the last 3 months.
- •15. Subjects with difficulties in attending the planned follow-up consultations.
- •16. Splenectomy or splenic dysfunction.
- •17. Pregnancy, puerperium or lactation.
- •18. Subjects with tattoos in the deltoid region of both arms.
- •19. Subjects with positive results to the determinations of HIV, Hepatitis B Surface Antigen, Hepatitis C Antibody and VDRL Serology. (For Phase I)
研究者
相似试验
进行中（未招募）
1 期
A Phase I/II Seamless Adaptive, Open label study to assess Safety, Tolerability, Radiation Dosimetry, Biodistribution, and diagnostic ability of a Novel 18F-labelled Tracer, SYN2, for Positron Emission Tomography in Myocardial Perfusion Imaging (SAFER) in Healthy Volunteers (phase I) and patients with suspected Coronary Artery Disease (phase II)EUCTR2019-003087-43-PLSynektik Spólka Akcyjna50
已完成
2 期
A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With PemphigusPemphigus VulgarisPemphigus FoliaceusNCT03334058argenx34
进行中（未招募）
1 期
A Study in a Type of Pancreatic Cancer that has Spread Beyond the PancreasMetastatic Pancreatic Ductal AdenocarcinomaMedDRA version: 19.0Level: LLTClassification code 10033599Term: Pancreatic adenocarcinoma metastaticSystem Organ Class: 100000004864EUCTR2016-002218-36-HUEli Lilly and Company106
进行中（未招募）
1 期
A Study in a Type of Pancreatic Cancer that has Spread Beyond the PancreasMetastatic Pancreatic Ductal AdenocarcinomaMedDRA version: 19.0 Level: LLT Classification code 10033599 Term: Pancreatic adenocarcinoma metastatic System Organ Class: 100000004864EUCTR2016-002218-36-ESilly S.A.256
进行中（未招募）
1 期
A Study in a Type of Pancreatic Cancer that has Spread Beyond the PancreasMetastatic Pancreatic Ductal AdenocarcinomaMedDRA version: 19.1 Level: LLT Classification code 10033599 Term: Pancreatic adenocarcinoma metastatic System Organ Class: 100000004864EUCTR2016-002218-36-FREli Lilly and Company256